AIM up on data supporting use of Ampligen as combination therapy for cancer

AIM ImmunoTech

21/04/2022 15:23

** Shares of AIM ImmunoTech Inc  AIM.A  rise 3.9% to $1.04
    ** Co provides clinical data that supports use of its
experimental therapy, Ampligen, as combination therapy along
with a class of cancer drugs called checkpoint blockade
therapies  urn:newsml:reuters.com:*:nFWN2WJ10U
    ** Ampligen anti-tumor potential is demonstrated with Merck'
 MRK.N  Keytruda in two studies for treatment of triple-negative
breast cancer and advanced recurrent ovarian cancer
    ** Data shows Ampligen as a single agent therapy as well as
in combination with latest powerful cancer therapies has 
potential to become a breakthrough therapy for some of the most
difficult to treat and deadly cancers - CEO
    ** Based on data seen to-date, AIM believes Ampligen has the
potential to expand into treatment of solid tumors
    ** Stock up ~14% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))